Dynamic Technology Lab Private Ltd Purchases Shares of 10,380 Hologic, Inc. $HOLX

Key Points

• Dynamic Technology Lab Private Ltd has acquired a new position in Hologic, Inc., purchasing 10,380 shares valued at approximately $641,000.
• Several hedge funds have also increased their investments in Hologic, with 94.73% of the stock now held by institutional investors.
• Analysts have recently upgraded Hologic's stock rating, with Citigroup raising its target price from $60.00 to $80.00, indicating growing confidence in the company's performance.

Dynamic Technology Lab Private Ltd acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,380 shares of the medical equipment provider's stock, valued at approximately $641,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Teza Capital Management LLC acquired a new stake in shares of Hologic in the 1st quarter valued at $251,000. USS Investment Management Ltd grew its position in shares of Hologic by 8.8% in the 1st quarter. USS Investment Management Ltd now owns 58,012 shares of the medical equipment provider's stock valued at $3,584,000 after buying an additional 4,684 shares during the last quarter. UniSuper Management Pty Ltd grew its position in shares of Hologic by 14.4% in the 1st quarter. UniSuper Management Pty Ltd now owns 34,810 shares of the medical equipment provider's stock valued at $2,150,000 after buying an additional 4,382 shares during the last quarter. Scientech Research LLC purchased a new position in shares of Hologic in the 1st quarter valued at $647,000. Finally, Sandler Capital Management grew its position in shares of Hologic by 20.9% in the 1st quarter. Sandler Capital Management now owns 53,824 shares of the medical equipment provider's stock valued at $3,325,000 after buying an additional 9,290 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on HOLX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Mizuho set a $75.00 target price on shares of Hologic in a research report on Thursday, July 31st. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Finally, Evercore ISI raised their price objective on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Stock Performance

Shares of HOLX stock traded down $1.93 during mid-day trading on Friday, hitting $64.45. The stock had a trading volume of 1,005,460 shares, compared to its average volume of 1,495,210. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The firm has a market cap of $14.33 billion, a PE ratio of 26.74, a PEG ratio of 2.41 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company's 50-day simple moving average is $66.43 and its 200-day simple moving average is $62.64.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the business earned $1.06 EPS. The business's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.